BioCentury
ARTICLE | Company News

AbbVie, Bristol-Myers, Gilead sales and marketing update

October 26, 2015 7:00 AM UTC

The committee made several changes to its recommendations for Daklinza and now recommends the drug in combination with Sovaldi in HCV genotype 1 untreated patients only if the patient has significant fibrosis; with or without ribavirin in HCV genotype 1 or 4 patients with compensated cirrhosis who are interferon-ineligible or intolerant; HCV genotype 3 non-cirrhotic patients with significant fibrosis and who are interferon-ineligible or intolerant; with ribavirin in HCV genotype 3 patients with compensated cirrhosis who are interferon ineligible or intolerant; and without Sovaldi but in combination with peginterferon alfa and ribavirin in previously treated and untreated HCV genotype 4 patients only if the person has significant fibrosis or compensated cirrhosis.

The committee also now recommends Viekirax with AbbVie’s Exviera dasabuvir and ribavirin in HCV genotype 1a patients with compensated cirrhosis; previously untreated patients with HCV genotype 4 infection; and treated and untreated HCV genotype 4 patients with compensated cirrhosis. ...